2025-08-29 10:07:49
Latest Post
Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd
Stock Report
Lupin Ltd posts Rs. 211.02 crore consolidated profit in Q2FY21
Posted On : 2020-11-04 23:11:14( TIMEZONE : IST )
LUPIN LTD. has reported financial results for the period ended September 30, 2020.
Financial Results (Q2 FY20-21) - QoQ Comparison
The company has reported total income of Rs.3859.96 crores during the period ended September 30, 2020 as compared to Rs.3571.14 crores during the period ended June 30, 2020.
The company has posted net profit / (loss) of Rs.211.02 crores for the period ended September 30, 2020 as against net profit / (loss) of Rs.106.90 crores for the period ended June 30, 2020.
The company has reported EPS of Rs.4.64 for the period ended September 30, 2020 as compared to Rs.2.35 for the period ended June 30, 2020.
| Financials | Q2 FY20-21 | Q1 FY20-21 | % Change |
| Total Income | ₹ 3859.96 crs | ₹ 3571.14 crs |  8.09% |
| Net Profit | ₹ 211.02 crs | ₹ 106.90 crs | 97.4% |
| EPS | ₹ 4.64 | ₹ 2.35 | 97.45% |
Financial Results (Q2 FY20-21) - YoY Comparison
The company has reported total income of Rs.3859.96 crores during the period ended September 30, 2020 as compared to Rs.4010.17 crores during the period ended September 30, 2019.
The company has posted net profit / (loss) of Rs.211.02 crores for the period ended September 30, 2020 as against net profit / (loss) of Rs.(127.07) crores for the period ended September 30, 2019.
The company has reported EPS of Rs.4.64 for the period ended September 30, 2020 as compared to Rs.(2.81) for the period ended September 30, 2019.
| Financials | Q2 FY20-21 | Q2 FY19-20 | % Change |
| Total Income | ₹ 3859.96 crs | ₹ 4010.17 crs |  -3.75% |
| Net Profit | ₹ 211.02 crs | ₹ (127.07) crs | 266.07% |
| EPS | ₹ 4.64 | ₹ (2.81) | 265.12% |
Financial Results (6 months ended FY 20-21) - YoY Comparison
The company has reported total income of Rs.7431.06 crores during the 6 months period ended September 30, 2020 as compared to Rs.7947.32 crores during the 6 months period ended September 30, 2019.
The company has posted net profit / (loss) of Rs.317.92 crores for the 6 months period ended September 30, 2020 as against net profit / (loss) of Rs.175.98 crores for the 6 months period ended September 30, 2019.
The company has reported EPS of Rs.6.98 for the 6 months period ended September 30, 2020 as compared to Rs.3.87 for the 6 months period ended September 30, 2019.
| Financials | Half-Year Ended FY20-21 | Half-Year Ended FY19-20 | % Change |
| Total Income | ₹ 7431.06 crs | ₹ 7947.32 crs | -6.5% |
| Net Profit | ₹ 317.92 crs | ₹ 175.98 crs | 80.66% |
| EPS | ₹ 6.98 | ₹3.87 | 80.36% |
Commenting on the results, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, "We are very pleased with the strong recovery of our business during the quarter, demonstrated by sequential growth across all our geographies, in particular US and India. This quarter marks the start of monetization of our complex generic pipeline with the launch of Etanercept biosimilar in Europe and generic Albuterol in the US. We expect to sustain the momentum on margin improvement led by optimization efforts underway and robust growth in our key businesses."
Shares of LUPIN LTD. was last trading in BSE at Rs.944.25 as compared to the previous close of Rs. 936.95. The total number of shares traded during the day was 132440 in over 4500 trades.
The stock hit an intraday high of Rs. 962.95 and intraday low of 940. The net turnover during the day was Rs. 125853178.
